Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginger for NAFLD in Type 2 Diabetes
NCT02289235Phase 1Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- May 2019
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Alanine Aminotransferase at 3 months. Started May 2019; status: completed.
02
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02289235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289235.